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Abstract
Background: The 22q11.2 deletion syndrome is the most common microdeletion syndrome in livebirths, but data
regarding its incidence in other populations is limited and also include ascertainment bias. This study was designed to
determine the incidence of the 22q11.2 deletion in miscarriage samples sent for clinical molecular cytogenetic testing.
Results: Twenty-six thousand one hundred one fresh product of conception (POC) samples were sent to a CLIA-
certified, CAP-accredited laboratory from April 2010–-May 2016 for molecular cytogenetic miscarriage testing using a
single-nucleotide polymorphism (SNP)-based microarray platform. A retrospective review determined the incidence of
the 22q11.2 deletion in this sample set. Fetal results were obtained in 22,451 (86%) cases, of which, 15 (0.07%) had a
microdeletion in the 22q11.2 region (incidence, 1/1497). Of those, 12 (80%) cases were found in samples that were
normal at the resolution of traditional karyotyping (i.e., had no chromosome abnormalities above 10 Mb in size) and
three (20%) cases had additional findings (Trisomy 15, Trisomy 16, XXY). Ten (67%) cases with a 22q11.2 deletion had
the common ~3 Mb deletion; the remaining 5 cases had deletions ranging in size from 0.65 to 1.5 Mb. A majority (12/
15) of cases had a deletion on the maternally inherited chromosome. No significant relationship between maternal age
and presence of a fetal 22q11.2 deletion was observed.
Conclusions: The observed incidence of 1/1497 for the 22q11.2 deletion in miscarriage samples is higher than the
reported general population prevalence (1/4000–1/6000). Further research is needed to determine whether the 22q11.
2 deletion is a causal factor for miscarriage.
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Background
The 22q11.2 deletion is the most common microdeletion
in humans, and is responsible for causing the distinct
range of features associated with the 22q11.2 deletion
syndrome, which can include congenital heart defects,
hypocalcemic hypoparathyroidism, T-cell mediated im-
mune deficiency, palate abnormalities, and intellectual
disability [1, 2]. The vast majority of 22q11.2 deletions
are de novo and are caused by meiotic nonallelic hom-
ologous recombination events between low-copy repeats
[3]. Although the majority (~90%) of patients share a
common 2.0–3.5 Mb deletion, approximately 7% of
patients have a smaller 1.5 Mb deletion nested within
the common deleted region, and ~3% have rarer atypical
deletions occurring outside this region [1, 3].
Population-wide estimates of the frequency of the
22q11.2 deletion have ranged from 1/4000 to 1/6000 [4, 5],
although, because none of these studies were prospective,
they are subject to both under-ascertainment and referral
biases. True population prevalence is therefore believed to
be higher [1]. Recent studies performed in prenatal cohorts
have indicated a higher prenatal incidence of ≥1/1000 for
the 22q11.2 deletion [6–8]. However, given that these stud-
ies were retrospective and involved a substantial percentage
of cases referred for invasive diagnostic procedures (e.g.,
due to ultrasound anomalies), these studies are also subject
to ascertainment bias. In the absence of a newborn screen-
ing program for the detection of 22q11.2 deletion syn-
drome, true incidence of the deletion remains unknown.* Correspondence: mmaisenbacher@natera.com
Natera, Inc., 201 Industrial Road, San Carlos 94070, CA, USA
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Maisenbacher et al. Molecular Cytogenetics  (2017) 10:6 
DOI 10.1186/s13039-017-0308-6
Recognizing the wide difference between prenatal and
postnatal estimates of prevalence, we sought to
determine the frequency of the 22q11.2 deletion in a
large cohort of miscarriage samples using a single-
nucleotide polymorphism (SNP)-based genotyping
microarray. In addition to identifying aneuploidies, the
SNP array-based method can detect subchromosomal
imbalances such as the 22q11.2 deletion at a much
higher resolution than traditional karyotyping (>0.5 Mb
vs. >10 Mb) [9–11]. Although chromosomal microarray
(CMA)-based approaches have already become routine
in the pediatric setting and are increasingly being used
for the testing of prenatal and adult samples [8, 12, 13],
the use of CMA as a first-line test for the analysis of
products of conception (POC) specimens is a relatively
new application of this technology [9, 14, 15].
Results
Of 26,101 total POC specimens tested, fetal results were
obtained for 22,451 (86%) cases. The remaining 3650
(14%) cases were excluded from the analysis due to hav-
ing maternal cell contamination (MCC) (n = 3549,
13.6%) or incomplete results (n = 101, 0.4%; Fig. 1). A
22q11.2 deletion was detected in 15 (0.07%) of the
22,451 cases with fetal results, yielding an overall inci-
dence of 1/1497. Two of the 15 cases with deletions
were present in a pair of twins; as the twins were dizyg-
otic, we considered the two cases as separate events.
Fifty-eight percent (13,053/22,451) of the POC speci-
mens with fetal results were considered abnormal (i.e.,
had chromosome abnormalities detectable by traditional
karyotyping, >10 Mb; Fig. 1). Of these, a 22q11.2 dele-
tion was identified in three cases (incidence, 1/4351),
one with a typical 3.5 Mb deletion and a finding of
Klinefelter syndrome (47,XXY), one with a nested
1.5 Mb deletion and a finding of trisomy 15, and the
third with a rarer 0.65 Mb deletion and a finding of tri-
somy 16 (Table 1). Among the 42% (9398/22,451) nor-
mal cases (i.e., no chromosome abnormalities detectable
by traditional karyotyping), a 22q11.2 deletion was iden-
tified in 12 cases (incidence, 1/783; Fig. 1). One of these
had an additional finding of maternal heterodisomic uni-
parental disomy of chromosome 17; no other cases had
additional findings detectable by the SNP-based array,
including other copy number variants (CNVs) (reso-
lution of >0.5 Mb; Table 1). Of the 12 ‘normal’ cases that
presented with the 22q11.2 deletion, three cases (two in
the set of twins) had 0.72 Mb deletions; the remaining
nine cases had the common 2.4–3.5 Mb deletion
(Table 1, Fig. 2). Each case is schematically represented
against the hg18 browser ideogram for chromosome 22.
The common A, B, C, and D low-copy repeats (LCRs)
for the 22q11.2 deletion are shown. There is one small
region (190 Kb) between LCR-B and LCR-C that is com-
mon to all 15 cases (Fig. 2). The only gene in this region
is SCARF2.
Eighty percent (12/15) of the 22q11.2 deletions identi-
fied were present on the maternally inherited chromo-
some (Table 1). Because mothers were not consented for
analysis of their samples outside the scope of fetal
results, it is unknown how many deletions on the mater-
nal chromosome were de novo versus inherited dele-
tions. Furthermore, the status of deletion on the
paternal chromosome (cases 13,14 and 15) cannot be de-
termined because paternal samples were not analyzed.
There was no significant difference in mean maternal
age (32.6 years; range, 19.0–41.3 years; standard devi-
ation [SD], 5.9) for the 15 cases with the deletion com-
pared with the entire analysis cohort (35.0 year; range,
15.0–52.0 year; SD, 5.3) (p = 0.38).
Gestational age information, which was available for
10 of the 15 POC specimens with the 22q11.2 deletion,
ranged from 6.4 to 13.6 weeks. Among those, 80% (8/10)
of the miscarriages occurred in the first trimester and
the remainder occurred early in the second trimester.
However, because gestational age at loss was available
for less than 20% of the study cohort in total, no infer-
ence could be drawn about the relationship between
gestational age and presence of the 22q11.2 deletion.
Discussion
Although gross chromosomal imbalances have been
shown to be present in approximately two-thirds of all
first trimester miscarriages [9, 16], relatively little infor-
mation on the frequency of the 22q11.2 deletion in mis-
carriage is available. To gain insight into this question,
we reviewed a large dataset of microarray results from
Fig. 1 Summary of the study cohort. #Had chromosome abnormalities
that could be detected at the resolution of traditional karyotyping
(≥10 Mb). *Had no apparent chromosome abnormalities that could be
detected at the resolution of traditional karyotyping
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POC specimens for the presence of 22q11.2 deletions.
Among 22,451 miscarriage samples with fetal results, we
observed the 22q11.2 deletion at an overall incidence of
1/1497, which is significantly more frequent than the
reported population prevalence of 1/4000–1/6000 [4, 5].
Possible explanations for this discrepancy include the
published general population prevalence potentially
being an underestimate, and/or that some affected
fetuses have major anomalies that lead to fetal demise
[17, 18]. For example, it is known, that cardiac defects
are the primary cause [87%] of mortality in infants with
the deletion [1]. Consistent with this, other recent stud-
ies have found a higher frequency of the 22q11.2 dele-
tion in prenatal cohorts and stillbirths (1/233 to 1/946)
[6–8, 13, 19].
The high variability of phenotypic presentation of the
22q11.2 deletion is well known, but it is not fully under-
stood why some individuals with the 22q11.2 deletion
are more severely affected than others [20, 21]. Recent
evidence suggests a role for additional genetic variants
that modify risk for congenital heart defects in some
patients with the deletion [22]. Conversely, other studies
have found no evidence of an increase in novel genome-
wide CNVs in patients with the 22q11.2 deletion [23].
However, there is still the potential for other undetect-
able mutations and /or environmental factors to impact
the severity of cases with the 22q11.2 deletion as was
proposed to modify clinical severity of the 16p21.2 dele-
tion and termed a ‘two-hit hypothesis’ [24].
In this study, we found the incidence of 22q11.2 dele-
tions in samples with additional abnormalities was
significantly lower than its incidence in samples without
them (incidence, 1/4351 vs. 1/783; p < 0.01). A previous
study comprising a subset of this study’s cohort (the first
2392 samples of 26,101 total) found that the distribution
of all subchromosomal CNVs, including the 22q11.2
deletion, was similarly skewed, with a higher proportion
of variants present in cytogenetically normal samples
[9]. The authors of that study suggested that the higher
incidence of copy-number changes in cytogenetically
Table 1 Description of cases with a 22q11.2 deletion
Case no. Categorya NCBI36/hg18 Genomic Coordinates
(GRCh38/hg38 Genomic Coordinates)






1.5 Maternal Trisomy 15
3 Abnormal 19,100,000–19,750,000
(20,415,710–21,065,711)
0.65 Maternal Trisomy 16
4 Normal 17,400,000–19,780,000
(19,032,487–21,095,711)


































aBased on the presence or absence of chromosome abnormalities that were detectable at the resolution of traditional karyotyping (i.e., ≥10 Mb)
bNon-identical twin gestation
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normal samples suggested that these findings “likely con-
tributed to miscarriage causality” [9]. That study also found
that the frequency of concurrent double aneuploidies in
miscarriage cohorts was lower than was expected based on
the reported incidence of each individual anomaly [9]. Pre-
sumably more than one significant genetic abnormality
leads to selective pressure against implantation, or against
continuation of pregnancies beyond 6 weeks. Likewise, if
the 22q11.2 deletion were an independent cause of miscar-
riage, it would likely be observed less frequently in cases
with additional chromosomal anomalies.
The combination of the 22q11.2 deletion’s high pheno-
typic variability, high frequency in stillbirth and prenatal
samples and high incidence found in this study suggests
that the published general population incidence may be
an underestimate and/or that the 22q11.2 deletion could
be a causal factor for miscarriage.
Other findings of this study were consistent with
previous studies. First, the majority (67%) of 22q11.2
deletions identified in this study had the common LCR-
A to LCR-D, 2.0–3.5 Mb-sized, deletion [1]; the
remaining deletions ranged in size from 0.65 to 1.5 Mb.
Second, 80% (12/15) of 22q11.2 deletions in this study
were on the maternally inherited chromosome, similar
to previous studies that found a higher proportion of
22q11.2 deletions on the maternal chromosome (76% in
prenatally diagnosed cases and 60% in postnatal cases)
[17, 23]. Although the exact reason for this skew toward
maternal origin is unknown, several factors have been
considered, including an increased rate of recombination
in this region in female germ cells, a mediating role of
the Y chromosome due to homology with the 22q11.2
region, reduced fitness for males with the deletion, and a
skewed inheritance pattern in male vs. female offspring
[23–25].
Interestingly, a region containing one known gene,
SCARF2, was common to all fifteen 22q11.2 deletion
cases. Mutations in SCARF2 are associated with Van
Den Ende-Gupta syndrome, an autosomal recessive
condition characterized by craniofacial and skeletal mal-
formations [26]. SCARF2 is thought to play a role in cell
signaling pathways but it is not well characterized. It
may play an important role the development of various
organ systems [26].
Approximately 7% of individuals who have a child with
a 22q11.2 deletion also have the deletion [1]. Therefore,
identification of a 22q11.2 deletion in a miscarriage
specimen should prompt evaluation of the parent(s) to
determine whether there are clinical and reproductive
risks for the parents. Additional medical screening and
care is recommended for all individuals with the 22q11.2
deletion, including adults diagnosed later in life [27, 28].
For adults with the deletion, the recurrence risk for each
subsequent pregnancy is 50%. Parents with an affected
child, but who do not have the deletion themselves, may
have a slightly elevated (~1%) recurrence risk in each
pregnancy, likely due to gonadal mosaicism [1]. Thus,
knowing if a POC specimen has the 22q11.2 deletion
can lead to better recurrence risk counseling and future
pregnancy management for families.
Fig. 2 Schematic of each deletion in the 22q11.2 region. Based on coordinates from the NCBI36/hg18 genome browser. The common A–-D low
copy repeats are shown in blue boxes
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The results of this study show a higher 22q11.2 dele-
tion incidence in the miscarriage population than litera-
ture reports of the live-born population. This implies
that either the population prevalence of the 22q11.2 de-
letion in the live-born population has been underesti-
mated or that the 22q11.2 deletion is a causative factor
in miscarriage. Further studies are needed to determine
the true incidence of the 22q11.2 deletion syndrome in
the live-born and prenatal population. Additionally, the
advantages of chromosomal microarray analysis support
its use as a first-line test for the analysis of POC
samples.
Methods
A retrospective review of 26,101 consecutive fresh POC
specimens received by a single Clinical Laboratory Im-
provement Act (CLIA)-certified, College of American
Pathologists (CAP)-accredited laboratory for clinical
miscarriage testing over a 6-year period (April 2010–
May 2016) was performed to determine the incidence of
the 22q11.2 deletion. A maternal blood sample was
requested with each specimen. For each patient, infor-
mation about maternal age, gestational age, egg donor
use, and indication for testing was requested, and all
samples were de-identified before review. Additional
clinical information including previous pregnancy his-
tory, method of conception, pregnancy records and fam-
ily history was not collected by the laboratory. This
study was granted a waiver of the requirement for docu-
mentation of informed consent by the institutional
review board (E&I ID# 15148-01).
Data on all clinical findings were previously published
for the first 2392 cases of this data set, which included
one case with the 22q11.2 deletion [9]. Additionally, all
syndromic CNVs in karyotypically normal samples from
17,424 cases in this data set were presented at the Ameri-
can Society of Reproductive Medicine 2016 meeting. This
included 6 cases with the 22q11.2 deletion [29].
Upon receipt at the commercial reference laboratory,
POC specimens were processed by separating chorionic
villi from maternal decidua using a standardized tech-
nique [30]. These, along with the maternal samples, were
genotyped using lllumina CytoSNP-12b microarrays,
which measures approximately 300,000 SNPs across the
genome (roughly one every 10 kb) according to the
manufacturer’s instructions (Illumina, Inc., San Diego,
CA). After a genomic sample is run on a SNP array the
results must pass an in-house quality control test before
further analysis is done. Genotyped samples were ana-
lyzed for DNA copy number, uniparental disomy (UPD),
parental origin of chromosome abnormalities, and ma-
ternal cell contamination (MCC) using the previously
described proprietary Parental SupportTM algorithm
[31]. In short, the allele ratios are calculated for each
locus across a chromosome, and the clustering of allele
ratios is indicative of the copy number for that chromo-
some. Comparison of the SNP identities between the
maternal and POC data is used to identify maternal cell
contamination, the parental origin of aneuploidy and un-
balanced chromosome segments. Since parents were not
consented for testing of their DNA nor is the father gen-
etic material tested, we are not able to determine
whether 22q11.2 deletions are inherited or de novo.
Samples were classified as ‘abnormal’ or ‘normal’ based
on the presence or absence of chromosome abnormal-
ities that could be detected at the resolution of trad-
itional karyotyping (i.e., >10 Mb). Coordinates for copy
number variants (CNVs) >0.5 Mb were entered into the
NCBI36/hg18 genome browser to determine clinical
significance based on genes affected and previously
reported overlapping CNVs. These coordinates were
then converted to the GRCh38/hg38 assembly coordi-
nates using the Lift Genome Annotations tool. To deter-
mine the statistical significance of maternal age values
and of the incidence of the 22q11.2 deletion, independ-
ent two-sample t-tests were performed.
Abbreviations
CNVs: Copy number variants; LCR: Low-copy repeats; Mb: Millions of base
pairs; MCC: Maternal cell contamination; POC: Products of conception;
SNP: Single-nucleotide polymorphism; UPD: Uniparental disomy
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